Both in Biotechnology
Repligen vs Halozyme Therapeutics
Over the past year RGEN returned +19.0% and HALO returned +95.5%; their daily moves had a correlation of 0.22.
RGEN +19.0% HALO +95.5%Growth of $1, one year, split-adjusted
| Metric | RGEN | HALO |
|---|---|---|
| Price | $178.72 | $129.42 |
| Market cap | $11.35B | $14.69B |
| Today | +0.25% | +0.62% |
| 1 month | +2.2% | +18.0% |
| 6 months | +42.1% | +95.1% |
| Year to date | +9.1% | +92.3% |
| 1 year | +19.0% | +95.5% |
| Revenue growth (YoY) | +10.9% | +47.7% |
| Gross margin | 53.0% | 83.5% |
| Net margin | −18.4% | 47.8% |
| P/E (TTM) | — | 35.5× |
| Price / sales | 14.1× | 8.8× |
| Net cash | $307.4M | -$1.92B |
| Dividend yield | — | — |
| Volatility (60d) | 47.3% | 27.8% |
| Short % of float | 12.8% | 12.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).